Rapidly progressive pediatric fibronectin glomerulopathy driven by a novel FN1 mutation (p.Thr1917del): implications for early diagnosis and recognition of systemic involvement Authors: Xiaobin Chen, Jun Huang, Yi Chen, Yunfan Zhang, Jinfeng Lin, Zengfeng Weng, Jingjing Liu, Guizhi Xia, Chengfeng Wang, Ai Feng, Yuxian Tang, Hannan Zhang, Xiaojing Nie Published: 2026 ABSTRACT BackgroundThis study characterizes a pediatric case of fibronectin glomerulopathy (FNG) caused by a novel FN1 variant and investigates the evidence for systemic involvement and genotype–phenotype correlations through a comprehensive literature review.MethodsWe report a female child diagnosed with FNG in February 2017 based on kidney biopsy and genetic testing at our institution. Clinical data and genetic reports were retrospectively analyzed. Fibronectin immunohistochemistry was performed on both kidney and gastric mucosal biopsy specimens. In addition, a literature review of Chinese and English databases was conducted to summarize genetically confirmed FNG cases.ResultsThe patient was a 9-year-old girl who presented with nephrotic-range proteinuria, microscopic hematuria, hypertension, and progressive kidney decline, culminating in kidney failure ten years after onset. Initial kidney pathology suggested atypical membranoproliferative glomerulonephritis (MPGN). Genetic analysis identified a novel de novo heterozygous deletion in the FN1 gene (NM_212482.5: c.5749_5751delACT; p.Thr1917del). Gastric mucosal immunohistochemistry revealed specific fibronectin deposition within the extracellular matrix, indicating systemic involvement. The comprehensive literature review of 72 patients revealed that the heparin-binding domain is a mutational hotspot, a finding consistent with the variant location in our case. The review also summarized disease management, progression, and post-transplant recurrence risk.ConclusionThis study presents the first reported pediatric FNG case internationally associated with the FN1 p.Thr1917del mutation and offers histological evidence suggestive of a possible systemic extracellular matrix proteinopathy. Our findings underscore the value of fibronectin staining and FN1 genetic testing in patients with atypical MPGN and broaden the disease’s clinical and genetic profile.Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary informationSupplementary informationThe online version contains supplementary material available at 10.1007/s00467-026-07298-3. Introduction Fibronectin glomerulopathy (FNG) is an extremely rare familial kidney disease, pathologically characterized by massive deposition of fibronectin (FN) in the glomerular mesangium. Clinically, it manifests as proteinuria, hypertension, and hematuria, typically following a chronic progressive course. A subset of patients may progress to kidney failure within 15–20 years [1–3]. FNG is an autosomal dominant disorder. Pathogenic heterozygous variants in the FN1 gene represent the primary genetic etiology of FNG. These variants induce conformational changes in fibronectin, leading to its abnormal accumulation and deposition within glomeruli. This process ultimately drives pathological alterations in key glomerular structures, including the basement membrane and mesangium [4, 5]. FNG caused by FN1 gene variants has been predominantly reported in adult patients worldwide, with most cases described as isolated reports. Pediatric-onset FNG is considerably rare, and its clinical course and genotype–phenotype characteristics remain to be further clarified. Therefore, this study provides a detailed report of a pediatric FNG case carrying a novel FN1 mutation, with childhood onset and progression to kidney failure. Through a literature review, we summarize the genetic mutation spectrum and clinical outcomes of FNG. This work aims to enhance clinicians’ understanding of this disease and provide new insights for precise diagnosis, genetic counseling, and exploration of future treatment strategies. Subjects and methods Subject The study subject was a female child who presented with hematuria and proteinuria at the Department of Pediatrics, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou, China. The diagnosis of FNG resulting from an FN1 gene variant was subsequently confirmed by kidney pathology and genetic testing. The study protocol received approval from the Medical Ethics Committee of the 900th Hospital (Approval No.: 2021–007), and written informed consent was provided by the child’s guardian. Methods Clinical data collection A retrospective analysis was conducted to comprehensively collect the patient’s clinical information, including present and past medical history, physical examination findings, laboratory test results (such as urinalysis, 24-h urinary protein quantification, liver and kidney function, electrolytes, and immunological indicators), and imaging studies. In addition, pathological reports from two kidney biopsies and records of treatment and follow-up were reviewed in detail. Fibronectin staining of kidney and gastric mucosa tissues Sections were prepared from the paraffin-embedded kidney puncture tissue obtained in April 2017. Following heat-induced antigen retrieval with citrate buffer (100 ×, pH 6.0), sections were incubated with rabbit anti-human fibronectin monoclonal antibody (Product No. RAB-0071, MXB Biotechnologies, China) according to standard immunohistochemical protocols. Staining results were evaluated by pathological examination. Formalin-fixed, paraffin-embedded blocks were prepared from both the patient's gastric mucosal biopsy obtained during gastroscopy in March 2024 and control gastric mucosal tissues. Tissue sections were prepared and subjected to antigen retrieval using sodium citrate buffer. Subsequently, immunohistochemical staining was performed following standard protocols using rabbit anti-human fibronectin monoclonal antibody (Product No. RAB-0071, MXB Biotechnologies, China) to evaluate the expression and localization of fibronectin in gastric tissues. Genetic testing and analysis Peripheral blood samples (2 mL each) were collected from the patient and her parents using EDTA anticoagulation. Genomic DNA was extracted using a Blood Genomic DNA Extraction Kit. WES was performed by Shenzhen BGI Medical Laboratory. Genomic DNA was fragmented and used to construct a sequencing library. Target regions were captured and enriched using the Roche KAPA Hyper Exome chip, and high-throughput sequencing was carried out on the MGISEQ-2000 platform. Quality control criteria included an average sequencing depth of ≥ 180 × in the target region, with > 95% of regions covered at > 20 ×. Bioinformatics analysis Variants were annotated and filtered based on the patient’s clinical information, population databases, disease databases, and bioinformatic prediction tools. Gene and variant nomenclature complied with the guidelines of the HUGO Gene Nomenclature Committee (HGNC) and the Human Genome Variation Society (HGVS), respectively. Pathogenicity of variants was assessed according to the standards of the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) [6], with additional reference to recommendations from the ClinGen Sequence Variant Interpretation Working Group and the Association for Clinical Genomic Science (ACGS), among other sources. Sanger sequencing validation Candidate pathogenic variants identified by WES were validated using Sanger sequencing. Specific primers were designed for PCR amplification, and sequencing was performed to confirm the presence and origin of the variant in the patient and her family members. Literature review A comprehensive literature search was performed using PubMed, EMBASE, and the Chinese Medical Association database (encompassing its affiliated journal articles), with the keywords “fibronectin glomerulopathy” and “FN1 mutation”. The search covered records from the inception of each database until September 2025. Case reports and clinical studies describing patients with genetically confirmed FN1-related FNG were screened for inclusion. Data on demographics, clinical features, genetic variants, and management were extracted for descriptive summary and analysis. Statistical analysis As this study comprises a case report and literature review, descriptive statistics were primarily employed. Continuous variables are presented as mean ± standard deviation or median (range), as appropriate. Categorical variables are summarized as frequency and percentage. Results Present illness history A 9-year-old girl was admitted in early 2017 with a two-year history of recurrent eyelid edema, proteinuria, and hematuria. Approximately two years prior, she had been evaluated at an external hospital for eyelid edema, where laboratory tests revealed albumin 37 g/L, urine protein 2 +, occult blood +, and 24-h urinary protein excretion of 0.823 g. She received glucocorticoid therapy for one month, which was subsequently discontinued by her parents. At the current admission, laboratory findings were as follows: urea nitrogen 6.8 mmol/L, creatinine 45.7 μmol/L, albumin 24.0 g/L, cholesterol 6.58 mmol/L, urine protein + +, occult blood + +, urinary red blood cell count 6–8/HP, and dysmorphic red blood cell rate of 78%. The 24-h urinary protein quantification was 3.716 g. Complement levels (C3, C4), anti-streptolysin O (ASO), immunoglobulins (IgG, IgA, IgM), antinuclear antibody (ANA), ANA profile, anti-dsDNA antibody, anti-cardiolipin antibody, and antineutrophil cytoplasmic antibody (ANCA) were all within normal limits. Imaging studies—including abdominal and cardiac ultrasonography, chest radiography, and electrocardiography—showed no abnormalities. Ambulatory blood pressure monitoring recorded values ranging from 107–162/62–107 mmHg. A kidney biopsy was performed approximately 2 months after admission. A second kidney biopsy and genetic testing were conducted at another institution approximately four and a half years after the initial presentation. Approximately five years after initial presentation, the patient underwent electronic gastroscopy for recurrent abdominal pain lasting over one month, which indicated non-atrophic gastritis. Due to persistent upper abdominal pain, a repeat gastroscopy approximately seven years after initial presentation, revealed a frost-like ulcer in the duodenal bulb and non-atrophic gastritis with erosion; the C13 urea breath test was negative. Throughout follow-up, proteinuria persisted without complete remission, and kidney function gradually declined. The patient has now progressed to kidney failure (Fig. 1).Fig. 1Longitudinal follow-up of the patient's urinary protein and creatinine levels alongside major therapeutic interventions. The X-axis represents the time of follow-up. The left Y-axis shows 24-h urinary protein excretion (g/24 h), represented by the yellow line. The right Y-axis shows serum creatinine (μmol/L), represented by the blue line. Key therapeutic interventions are indicated at the top: PSL (prednisolone), MMF (mycophenolate mofetil) and benazepril. Blue arrows indicate courses of high-dose methylprednisolone therapy. Black arrows indicate the timing of the two renal biopsies. MMF, mycophenolate mofetil Longitudinal follow-up of the patient's urinary protein and creatinine levels alongside major therapeutic interventions. The X-axis represents the time of follow-up. The left Y-axis shows 24-h urinary protein excretion (g/24 h), represented by the yellow line. The right Y-axis shows serum creatinine (μmol/L), represented by the blue line. Key therapeutic interventions are indicated at the top: PSL (prednisolone), MMF (mycophenolate mofetil) and benazepril. Blue arrows indicate courses of high-dose methylprednisolone therapy. Black arrows indicate the timing of the two renal biopsies. MMF, mycophenolate mofetil Personal and family history No significant personal or family medical history was reported. Treatment and follow-up course Following admission, the patient was initiated on prednisone acetate (initial dose 2 mg/kg, maintained for 8 weeks and subsequently tapered), benazepril, and amlodipine besylate. After the initial pathology results were obtained, she received two courses of methylprednisolone (10 mg/kg) over a total of 6 days. This intervention led to a mild reduction in urinary protein levels and an increase in serum albumin. Mycophenolate mofetil (MMF) was subsequently added to the regimen. However, after one year, the family voluntarily discontinued MMF and switched to traditional Chinese medicine. Following this change, the patient's edema worsened and kidney function progressively declined. Upon receipt of the second pathology report in late 2021, therapy with MMF combined with an ACEI was reinstated but discontinued after 6 months due to lack of significant clinical improvement. The patient is currently maintained on hemodialysis in 2025. First kidney biopsy (Spring 2017). Light microscopy: A total of 9 glomeruli were examined, showing enlarged glomerular volume (approximately 20–25 μm). One glomerulus exhibited global sclerosis. Capillary tufts displayed diffuse global endocapillary hyperplasia. Significant mesangial lesions were observed (cellularity + + +, matrix + + +), characterized by diffuse global severe nodular hyperplasia. Basement membrane alterations were not prominent, and podocytes appeared unaffected. Tubular injury was mild, with focal calcification noted. Kidney interstitial fibrosis was present (+), accompanied by inflammatory cell infiltration (< 10%), consisting predominantly of lymphocytes and monocytes (+). Kidney vascular changes were mild. Immunohistochemistry revealed deposits of IgG, IgM, IgA, C3d, and C4d in the mesangium and capillary loops, ranging from (+) to (+ +). No C1q deposition was detected. The initial pathological diagnosis was diffuse atypical MPGN with massive protein deposits, focal global glomerulosclerosis, mild tubular atrophy, and interstitial fibrosis. Fibronectin immunohistochemistry: Staining performed during the recent review of the case showed strong positivity. Electron microscopy: The glomerular mesangial area was markedly expanded, with evident mesangial cell and matrix hyperplasia. Numerous high-density electron-dense deposits were observed in the mesangial and paramesangial regions, as well as in the subendothelial spaces of capillary loops. Capillary lumens demonstrated segmental narrowing, collapse, and occlusion, accompanied by segmental mesangial interposition. Focal fusion of podocyte foot processes was evident. Bowman's capsule, tubules, and interstitium showed no significant abnormalities. At high magnification, the electron-dense deposits exhibited a fine granular and fibrillar ultrastructure, consistent with fibronectin accumulation (Fig. 2).Fig. 2Histopathological, immunohistochemical, and ultrastructural features of the renal biopsy. Note: A PAS staining (× 200) shows globally enlarged glomeruli with accentuated lobulation. B PASM-Masson staining (× 400) highlights prominent fuchsinophilic deposits within the mesangium. C Immunohistochemistry for C4d (× 400) demonstrated mild to moderate (1 + to 2 +) segmental deposition along the outer aspect of the glomerular basement membrane. D Immunohistochemistry for plasma fibronectin (× 200) showed heavy deposition within the subendothelial and mesangial areas of the glomerulus. E Electron micrograph (× 4 K; scale bar = 10 μm) shows numerous electron-dense deposits in the mesangial areas and subendothelial regions of the glomerular capillary loops, accompanied by mesangial matrix expansion and segmental compression of the capillary lumina. Focal fusion of podocyte foot processes is also evident. F High-power electron micrograph (× 50 K; scale bar = 1000 nm/1 μm) reveals the fine granular and fibrillar ultrastructure of the deposits (↗), with randomly arranged fibrils measuring approximately 10 nm in diameter, consistent with fibronectin accumulation. Extensive fusion of podocyte foot processes is observed Histopathological, immunohistochemical, and ultrastructural features of the renal biopsy. Note: A PAS staining (× 200) shows globally enlarged glomeruli with accentuated lobulation. B PASM-Masson staining (× 400) highlights prominent fuchsinophilic deposits within the mesangium. C Immunohistochemistry for C4d (× 400) demonstrated mild to moderate (1 + to 2 +) segmental deposition along the outer aspect of the glomerular basement membrane. D Immunohistochemistry for plasma fibronectin (× 200) showed heavy deposition within the subendothelial and mesangial areas of the glomerulus. E Electron micrograph (× 4 K; scale bar = 10 μm) shows numerous electron-dense deposits in the mesangial areas and subendothelial regions of the glomerular capillary loops, accompanied by mesangial matrix expansion and segmental compression of the capillary lumina. Focal fusion of podocyte foot processes is also evident. F High-power electron micrograph (× 50 K; scale bar = 1000 nm/1 μm) reveals the fine granular and fibrillar ultrastructure of the deposits (↗), with randomly arranged fibrils measuring approximately 10 nm in diameter, consistent with fibronectin accumulation. Extensive fusion of podocyte foot processes is observed Second kidney biopsy (late 2021, external hospital): Among 25 glomeruli examined, 12 were sclerotic. Gastric mucosal pathology (early 2024): Histological examination revealed generally normal gastric mucosa. To investigate whether the FN1 gene mutation led to extra-kidney fibronectin deposition, we performed fibronectin immunohistochemical staining on gastric mucosal biopsy specimens from both the patient and control subjects (individuals with abdominal pain but histologically normal gastric mucosa and no history of kidney disease). The results demonstrated no significant specific staining in the gastric glandular epithelium of either group. However, distinct fibronectin staining was observed in the extracellular matrix of the periglandular stroma, with notably more abundant deposition in the patient compared to the control group (Fig. 3).Fig. 3Gastric mucosa hematoxylin and eosin (H&E) and fibronectin immunohistochemical (IHC) (× 100). A Patient H&E. B Patient IHC shows strong fibronectin deposition specifically within the extracellular matrix. C Normal control H&E. D Normal control IHC shows minimal staining. The fibronectin deposition is significantly more abundant and localized to the extracellular matrix in the patient, with no epithelial involvement Gastric mucosa hematoxylin and eosin (H&E) and fibronectin immunohistochemical (IHC) (× 100). A Patient H&E. B Patient IHC shows strong fibronectin deposition specifically within the extracellular matrix. C Normal control H&E. D Normal control IHC shows minimal staining. The fibronectin deposition is significantly more abundant and localized to the extracellular matrix in the patient, with no epithelial involvement Whole exome gene testing The identified variant was located in the FN1 gene (chr2:216,241,357–216,241,359), designated as NM_212482.1:c.5749_5751delACT, resulting in the p.Thr1917del amino acid change. This heterozygous in-frame deletion of three base pairs in exon 36 leads to the loss of a threonine residue and follows an autosomal dominant inheritance pattern. Sanger sequencing confirmed that the variant was present only in the proband and absent in both asymptomatic parents, supporting a de novo origin, though parental germline mosaicism could not be entirely excluded. In silico prediction tools MutationTaster and SIFT classified the variant as “disease-causing” and “deleterious”, respectively. Bioinformatic analysis revealed that the affected residue is completely conserved across mammalian species. Homology modeling of wild-type and mutant fibronectin was performed using Swiss-Model, with subsequent structural visualization and analysis conducted in PyMOL. Comparative analysis demonstrated that the p.Thr1917del deletion induces significant local conformational rearrangement, resulting in specific disruption of β-sheet architecture within the heparin-binding domain (Fig. 4).Fig. 4Pedigree, genetic sequencing, cross-species conservation, and structural model of the FN1 variant. A Family pedigree. White square (□) represent males, white circle (○) represent females, black circle (●) indicates the affected female patient, and the arrow (↗) denotes the proband. B Sanger sequencing chromatogram showing the heterozygous FN1 mutation c.5749_5751delACT. C Evolutionary conservation analysis of the p.Thr1917 residue across species. The red arrow points to the conserved threonine at position 1917. D Schematic diagram of the domain structure of fibronectin. Key domains are indicated as follows: , type I domains; , type II domains; , type III domains; , alternative splicing sites in type III domains. The Heparin-binding domain I (Hep-I) is highlighted in red, and the Integrin-binding domain (IBD) is shown in yellow. The black arrow indicates the location of the patient's mutation. E Comparative structural models of wild-type and mutant Fibronectin protein Pedigree, genetic sequencing, cross-species conservation, and structural model of the FN1 variant. A Family pedigree. White square (□) represent males, white circle (○) represent females, black circle (●) indicates the affected female patient, and the arrow (↗) denotes the proband. B Sanger sequencing chromatogram showing the heterozygous FN1 mutation c.5749_5751delACT. C Evolutionary conservation analysis of the p.Thr1917 residue across species. The red arrow points to the conserved threonine at position 1917. D Schematic diagram of the domain structure of fibronectin. Key domains are indicated as follows: , type I domains; , type II domains; , type III domains; , alternative splicing sites in type III domains. The Heparin-binding domain I (Hep-I) is highlighted in red, and the Integrin-binding domain (IBD) is shown in yellow. The black arrow indicates the location of the patient's mutation. E Comparative structural models of wild-type and mutant Fibronectin protein According to ACMG/AMP guidelines, the variant was classified as Likely Pathogenic based on the following evidence: PS2_moderate: De novo occurrence (without parental confirmation via trio-based WES). PM1: Located in the mutational hotspot of heparin-binding domain 2, a key functional region. PM2: Absent in population databases (1000 Genomes, ExAC, GnomAD, ESP6500). PM4: In-frame deletion in a non-repeat region resulting in a protein length change. PP4: The patient’s phenotype is highly specific for FN1-related FNG. No previous reports of this variant were found in the HGMD or Var Card databases. In combination with the patient’s clinical and pathological findings, this FN1 variant was concluded to be the underlying genetic cause of FNG in this case. Literature review results The literature search identified approximately 130 reported cases of FNG worldwide, involving nearly 100 families. The primary presenting symptom was edema or incidental findings on routine examination. FNG can manifest at any age, with reported onset ranging from 4 months to 88 years [7, 8], and the youngest age at diagnosis being 1 year [9]. Seventy-two patients (Table 1) underwent FN1 gene testing, of which 68 cases detected FN1 variant sites, with a positive detection rate of 94.44%. Four cases were negative for FN1 gene testing [20, 28, 29, 31], suggesting that FNG pathogenesis may in some cases involve mechanisms independent of FN1. Among them, there were 66.66% (48/72) with family history. No significant sex predominance was observed: 58.33% (42/72) of patients were female and 41.66% (30/72) were male. Disease onset occurred predominantly between 20 and 50 years of age, accounting for 51.39% (32/72) of cases, consistent with previous literature. The average age of onset was 24.20 ± 17.90 years, and the average age at disease onset was 31.51 ± 19.09 years. Among them, 30.55% (22/72) had their onset during childhood (≤ 18 years). Table 1Summary of clinical, genetic and therapeutic efficacy data from 72 reported cases of fibronectin glomerulopathy (FNG)CaseFamily HistoryaAgeb (y)SexcHematuriad24 h-UPro/UPCReHypertensionfeGFRgsCrhFN1 variant/protein changeFN1 variant locationiTreatmentjTreatment responsekAuthor/reference F1 + 29/29F + -/10.1 + 62.70.88c.5888-2A > G/-Hep2%1 ③④PRNagayama et al. [10]F2 + 49/49F + -/0.91 + 50.20.94c.5888-2A > G/-Hep2① ~ ⑤NRF3-4/2.5F + -/1.56 + > 1350.176c.1250G > T/p.Gly417ValFN II2%1 ⑥NRKalmár et al. [11]F4-32/32F-4.9/- + 126.60.405c.5888-1G > C/-Ivs36%1 ⑧PRYang et al. [12]F5 + 75/75F + 3.63/3.99 + 381.36c.2918A > G/Y973CHep3%1 ⑥PRChoi et al. [13]F6 + 57/20M + -/1.21 + 53.71.12c.4415_4417del/p.P1472delIBD①③NRHata et al. [14]F7 + 37/5M--/1.0 + -2.2c.2918A > G/Y973CHep3④⑥/③NR/PRKlair et al. [15]F8 + 23/23F--/5.3 + -1.1c.3049 T > C/p.Trp1017ArgHep3①③NRBatal et al. [16]F9-32/32F-----5888-1G > C/-Ivs36--She et al. [17]F10-13/13M + 2.38/1.56--1.15c.3415G > A/p.V1139IFNIII6--Qiu et al. [18]F11 + 4/3F + 0.598/- + -Normalc.2918A > G/Y973CHep3-NRLi et al. [19]F12-44/44F-15.09/- + -0.48Negative-①③④PRLi et al. [20]F13 + 2/0.33F + 0.05/1.78--0.24c.2984C > T/p.T995IHep3--Yang et al. [7]F14-47/27F- > 3.5/> 2--0.92c.5921 T > C/p.Leu1974ProHep2%1 ③KTWei et al. [21]F15-11/11M-----c.5602G > A/p.V1868MHep2--Yu et al. [22]F16-4/4MHormone-resistant nephrotic syndrome without hematuriac.6275C > T/P.2092LIIICS①NRXiao et al. [9]F17-1/1Fc.3910G > A/p.A1304TFNIII8①NRF18-15/15Fc.5688G > C/p.Q1896HHep2①NRF19 + 27/27F-3/4-600.7c.2918A > G/p.Tyr973CysHep2①③PRGoldman et al. [23]F20 + 21/11F + -/1.89 + 11.34.6c2915A > G/pY972cHep3%1 ⑥PRHara et al. [24]F21 + 47/47M + 5/- + 721.2c.5962_5964del/p.Ile1988delHep2NRDos et al. [5]F22 + 14/14M + 5.42/- + 1380.73Hep2③NRF23_27/17M- > 3.5/> 2---c.3051G > T/p.W1017CHep3①④NRAslam et al. [25]F24 + 54/23M + --382.1c.3051G > T/p.W1017CHep3-KTF25-49/35F + 5.09/--46.31.3c.4374_4376del/p.1459FNIII 10%1 ③④NRXu et al. [26]F26-19/19F + 0.62/--148.60.6c.4374_4376del/p.1459FNIII 10③NRF27-32/24F + 2.96/--189.20.5c.5773 T > C/p.T1925AHep2①③④NRF28-14/14F + 1.84/--161.10.6c.2918A > G/Y973CHep3⑦NRF29 + 45/45F + -/3.6-82.60.61c.5821 T < C/p.L1974PHep2③④NRHirashio et al. [27]F30-22/22F + > 3.5/> 2--11.89Negative--KFMandal et al. [28]F31 + 21/20F + -/3.38-0.78Negative-③NRTakii et al. [29]F32 + 20/6M + -/0.86-92.1-c.2918A > G/p.Tyr973CysHep3①-Ohtsubo et al. [30]F33 + 13/9F--/1.6-115-c.2918A > G/p.Tyr973CysHep3①-F34 + 35/26F + KF + -Normalc.5775G > C/p.Trp1925CysHep2-HDF35 + 54/13F + ---Normalc.4414_4416del/p.Pr1472delIBD-KTF36-35/12F_-/5.85-76.3-c.2918A > G/p.Tyr973CysHep3--F37 + 15/12F + -/0.51 + 86.5-c.2918A > G/p.Tyr973CysHep3①-F38-53/20F--/11.8 + 48-c.5921 T > C/p.Leu1974ProHep2①-F39_16/15M--/0.44 + 124.1-c.2906C > T/p.Pro969LeuHep3--F40-74/61M + -/3.56 + 63-c.5921 T > C/p.Leu1974ProHep2①-F41 + 38/38F + -/4.9 + 55.3-c.4414_4416del/p.Pro1472delIBD①-F42-14/11F + -/10.1-123.4-c.2918A > G/p.Tyr973CysHep3①⑥-F43-64/63M + -/4.6 + 46.3-c.5858_5884del/p.Lys1953_Ile1961delHep2--F44-78/77F + -/10.2 + -0.89Negative-⑩KFIshimoto et al. [31]F45 + 24/24M-1/--1230.82c.2918A > G/p.Y973CHep3③NRBaydar et al. [32]F46 + -M-2 g/---Normalc.2918A > G/p.Y973CHep3③NRF47 + 50/30F + -/4.8-760.8c.2918A > G/p.Y973CHep3③NRNadamuni et al. [33]F48 + 54/44M--/0.3--1.4c.5773 T > A/p. W1925RHep2--Castelletti et al. [4]F49 + 40/?M-- + -2.2c.5773 T > A/p. W1925RHep2-DeathF50 + 46/35M- > 3.5/> 2 + -1.5c.5773 T > A/p. W1925RHep2-NRF51 + 40/27M + 0.74/---0.8c.5773 T > A/p. W1925RHep2-NRF52 + 14/12M + 7.46/- + -0.7c.5773 T > A/p. W1925RHep2--F53 + 74/59F- > 3.5/> 2 + -4.0c.5773 T > A/p. W1925RHep2-KFF54 + 41/18M-4.16/- + -1.22c.5773 T > A/p. W1925RHep2-KTF55 + 35/16M + > 3.5/> 2--1.5c.5773 T > A/p. W1925RHep2-KTF56-61 + The father and his five children (four daughters and one son) developed proteinuria at ages 14, 16, 26, 43, and 47. Among them, three developed kidney failure at ages 33, 34, and 35, two underwent kidney transplants, and one received hemodialysis (HD)c.5921 T > G/P.L1974RHep2--F62 + 25/25F--/5-80-c.2918A > G/p.Y973CHep3⑩NRF63 + 14/11F- > 3.5/> 2--0.6c.2918A > G/p.Y973CHep3--F64 + 38/29M- > 3.5/> 2---c.2918A > G/p.Y973CHep3--F65 + 21/21M-2.8/----c.2918A > G/p.Y973CHep3--F66 + 21/?M-----c.2918A > G/p.Y973CHep3--F67-70 + All four siblings (three males and one female) exhibited proteinuria. Two were diagnosed with FNG through biopsy, while one 18-year-old patient developed proteinuria and progressed to kidney failure by age 33. The oldest patient, aged 42, had a serum creatinine level of 2–3 mg/dlc.2918A > G/p.Y973CHep3--F71 + 11/3F + -/8 + -0.2c.2918A > G/p.Y973CHep3--F72-9/7F + 3.716/- + 138.345.7c.5749_5751delACT/p.Thr1917delHep2① ~ ④PRThe caseaFamily history: “ + ” positive; “-” negativebAge: Data are presented as age at consultation/age at onset (years)cSex: F, female; M, maledHematuria: “ + ” present; “-” absente24UPR, 24-h urinary protein excretion (g/24h); UPCR, urine protein-to-creatinine ratio (g/g). Elevated levels defined as 24UPR > 0.15 g/24h, or UPCR ≥ 0.3 g/g in adults and ≥ 0.2 g/g in childrenfHypertension: “ + ” present; “-” absentgeGFR, estimated glomerular filtration rate (ml/min/1.73 m2). Reduced eGFR defined as < 90 ml/min/1.73 m2 in children/adolescents (> 2 years) and < 60 ml/min/1.73 m2 in adultshScr, serum creatinine (mg/dL). Normal range: 0.6–1.2 (male), 0.5–1.1 (female)iHep2/Hep3, heparin-binding domain 2/3; IBD, integrin-binding domain; FN II/FN III, fibronectin type II/III domain; Ivs, intronic variant affecting splicingjTreatments:①Corticosteroids (e.g., prednisone); ②High-dose corticosteroids (e.g., methylprednisolone pulse therapy); ③RASi; ④Immunomodulators (e.g., mycophenolate mofetil); ⑤ Aspirin; ⑥ Other antihypertensives (e.g., calcium channel blockers); ⑦Traditional Chinese medicine; ⑧Sodium-glucose cotransporter-2 inhibitors(SGLT2i); ⑨ Rituximab; ⑩ IndomethacinkPR, partial remission; NR, no remission; KT, CKD stage 5 treated by kidney transplant; KF, kidney failure Table 1Summary of clinical, genetic and therapeutic efficacy data from 72 reported cases of fibronectin glomerulopathy (FNG)CaseFamily HistoryaAgeb (y)SexcHematuriad24 h-UPro/UPCReHypertensionfeGFRgsCrhFN1 variant/protein changeFN1 variant locationiTreatmentjTreatment responsekAuthor/reference F1 + 29/29F + -/10.1 + 62.70.88c.5888-2A > G/-Hep2%1 ③④PRNagayama et al. [10]F2 + 49/49F + -/0.91 + 50.20.94c.5888-2A > G/-Hep2① ~ ⑤NRF3-4/2.5F + -/1.56 + > 1350.176c.1250G > T/p.Gly417ValFN II2%1 ⑥NRKalmár et al. [11]F4-32/32F-4.9/- + 126.60.405c.5888-1G > C/-Ivs36%1 ⑧PRYang et al. [12]F5 + 75/75F + 3.63/3.99 + 381.36c.2918A > G/Y973CHep3%1 ⑥PRChoi et al. [13]F6 + 57/20M + -/1.21 + 53.71.12c.4415_4417del/p.P1472delIBD①③NRHata et al. [14]F7 + 37/5M--/1.0 + -2.2c.2918A > G/Y973CHep3④⑥/③NR/PRKlair et al. [15]F8 + 23/23F--/5.3 + -1.1c.3049 T > C/p.Trp1017ArgHep3①③NRBatal et al. [16]F9-32/32F-----5888-1G > C/-Ivs36--She et al. [17]F10-13/13M + 2.38/1.56--1.15c.3415G > A/p.V1139IFNIII6--Qiu et al. [18]F11 + 4/3F + 0.598/- + -Normalc.2918A > G/Y973CHep3-NRLi et al. [19]F12-44/44F-15.09/- + -0.48Negative-①③④PRLi et al. [20]F13 + 2/0.33F + 0.05/1.78--0.24c.2984C > T/p.T995IHep3--Yang et al. [7]F14-47/27F- > 3.5/> 2--0.92c.5921 T > C/p.Leu1974ProHep2%1 ③KTWei et al. [21]F15-11/11M-----c.5602G > A/p.V1868MHep2--Yu et al. [22]F16-4/4MHormone-resistant nephrotic syndrome without hematuriac.6275C > T/P.2092LIIICS①NRXiao et al. [9]F17-1/1Fc.3910G > A/p.A1304TFNIII8①NRF18-15/15Fc.5688G > C/p.Q1896HHep2①NRF19 + 27/27F-3/4-600.7c.2918A > G/p.Tyr973CysHep2①③PRGoldman et al. [23]F20 + 21/11F + -/1.89 + 11.34.6c2915A > G/pY972cHep3%1 ⑥PRHara et al. [24]F21 + 47/47M + 5/- + 721.2c.5962_5964del/p.Ile1988delHep2NRDos et al. [5]F22 + 14/14M + 5.42/- + 1380.73Hep2③NRF23_27/17M- > 3.5/> 2---c.3051G > T/p.W1017CHep3①④NRAslam et al. [25]F24 + 54/23M + --382.1c.3051G > T/p.W1017CHep3-KTF25-49/35F + 5.09/--46.31.3c.4374_4376del/p.1459FNIII 10%1 ③④NRXu et al. [26]F26-19/19F + 0.62/--148.60.6c.4374_4376del/p.1459FNIII 10③NRF27-32/24F + 2.96/--189.20.5c.5773 T > C/p.T1925AHep2①③④NRF28-14/14F + 1.84/--161.10.6c.2918A > G/Y973CHep3⑦NRF29 + 45/45F + -/3.6-82.60.61c.5821 T < C/p.L1974PHep2③④NRHirashio et al. [27]F30-22/22F + > 3.5/> 2--11.89Negative--KFMandal et al. [28]F31 + 21/20F + -/3.38-0.78Negative-③NRTakii et al. [29]F32 + 20/6M + -/0.86-92.1-c.2918A > G/p.Tyr973CysHep3①-Ohtsubo et al. [30]F33 + 13/9F--/1.6-115-c.2918A > G/p.Tyr973CysHep3①-F34 + 35/26F + KF + -Normalc.5775G > C/p.Trp1925CysHep2-HDF35 + 54/13F + ---Normalc.4414_4416del/p.Pr1472delIBD-KTF36-35/12F_-/5.85-76.3-c.2918A > G/p.Tyr973CysHep3--F37 + 15/12F + -/0.51 + 86.5-c.2918A > G/p.Tyr973CysHep3①-F38-53/20F--/11.8 + 48-c.5921 T > C/p.Leu1974ProHep2①-F39_16/15M--/0.44 + 124.1-c.2906C > T/p.Pro969LeuHep3--F40-74/61M + -/3.56 + 63-c.5921 T > C/p.Leu1974ProHep2①-F41 + 38/38F + -/4.9 + 55.3-c.4414_4416del/p.Pro1472delIBD①-F42-14/11F + -/10.1-123.4-c.2918A > G/p.Tyr973CysHep3①⑥-F43-64/63M + -/4.6 + 46.3-c.5858_5884del/p.Lys1953_Ile1961delHep2--F44-78/77F + -/10.2 + -0.89Negative-⑩KFIshimoto et al. [31]F45 + 24/24M-1/--1230.82c.2918A > G/p.Y973CHep3③NRBaydar et al. [32]F46 + -M-2 g/---Normalc.2918A > G/p.Y973CHep3③NRF47 + 50/30F + -/4.8-760.8c.2918A > G/p.Y973CHep3③NRNadamuni et al. [33]F48 + 54/44M--/0.3--1.4c.5773 T > A/p. W1925RHep2--Castelletti et al. [4]F49 + 40/?M-- + -2.2c.5773 T > A/p. W1925RHep2-DeathF50 + 46/35M- > 3.5/> 2 + -1.5c.5773 T > A/p. W1925RHep2-NRF51 + 40/27M + 0.74/---0.8c.5773 T > A/p. W1925RHep2-NRF52 + 14/12M + 7.46/- + -0.7c.5773 T > A/p. W1925RHep2--F53 + 74/59F- > 3.5/> 2 + -4.0c.5773 T > A/p. W1925RHep2-KFF54 + 41/18M-4.16/- + -1.22c.5773 T > A/p. W1925RHep2-KTF55 + 35/16M + > 3.5/> 2--1.5c.5773 T > A/p. W1925RHep2-KTF56-61 + The father and his five children (four daughters and one son) developed proteinuria at ages 14, 16, 26, 43, and 47. Among them, three developed kidney failure at ages 33, 34, and 35, two underwent kidney transplants, and one received hemodialysis (HD)c.5921 T > G/P.L1974RHep2--F62 + 25/25F--/5-80-c.2918A > G/p.Y973CHep3⑩NRF63 + 14/11F- > 3.5/> 2--0.6c.2918A > G/p.Y973CHep3--F64 + 38/29M- > 3.5/> 2---c.2918A > G/p.Y973CHep3--F65 + 21/21M-2.8/----c.2918A > G/p.Y973CHep3--F66 + 21/?M-----c.2918A > G/p.Y973CHep3--F67-70 + All four siblings (three males and one female) exhibited proteinuria. Two were diagnosed with FNG through biopsy, while one 18-year-old patient developed proteinuria and progressed to kidney failure by age 33. The oldest patient, aged 42, had a serum creatinine level of 2–3 mg/dlc.2918A > G/p.Y973CHep3--F71 + 11/3F + -/8 + -0.2c.2918A > G/p.Y973CHep3--F72-9/7F + 3.716/- + 138.345.7c.5749_5751delACT/p.Thr1917delHep2① ~ ④PRThe caseaFamily history: “ + ” positive; “-” negativebAge: Data are presented as age at consultation/age at onset (years)cSex: F, female; M, maledHematuria: “ + ” present; “-” absente24UPR, 24-h urinary protein excretion (g/24h); UPCR, urine protein-to-creatinine ratio (g/g). Elevated levels defined as 24UPR > 0.15 g/24h, or UPCR ≥ 0.3 g/g in adults and ≥ 0.2 g/g in childrenfHypertension: “ + ” present; “-” absentgeGFR, estimated glomerular filtration rate (ml/min/1.73 m2). Reduced eGFR defined as < 90 ml/min/1.73 m2 in children/adolescents (> 2 years) and < 60 ml/min/1.73 m2 in adultshScr, serum creatinine (mg/dL). Normal range: 0.6–1.2 (male), 0.5–1.1 (female)iHep2/Hep3, heparin-binding domain 2/3; IBD, integrin-binding domain; FN II/FN III, fibronectin type II/III domain; Ivs, intronic variant affecting splicingjTreatments:①Corticosteroids (e.g., prednisone); ②High-dose corticosteroids (e.g., methylprednisolone pulse therapy); ③RASi; ④Immunomodulators (e.g., mycophenolate mofetil); ⑤ Aspirin; ⑥ Other antihypertensives (e.g., calcium channel blockers); ⑦Traditional Chinese medicine; ⑧Sodium-glucose cotransporter-2 inhibitors(SGLT2i); ⑨ Rituximab; ⑩ IndomethacinkPR, partial remission; NR, no remission; KT, CKD stage 5 treated by kidney transplant; KF, kidney failure Summary of clinical, genetic and therapeutic efficacy data from 72 reported cases of fibronectin glomerulopathy (FNG) aFamily history: “ + ” positive; “-” negative bAge: Data are presented as age at consultation/age at onset (years) cSex: F, female; M, male dHematuria: “ + ” present; “-” absent e24UPR, 24-h urinary protein excretion (g/24h); UPCR, urine protein-to-creatinine ratio (g/g). Elevated levels defined as 24UPR > 0.15 g/24h, or UPCR ≥ 0.3 g/g in adults and ≥ 0.2 g/g in children fHypertension: “ + ” present; “-” absent geGFR, estimated glomerular filtration rate (ml/min/1.73 m2). Reduced eGFR defined as < 90 ml/min/1.73 m2 in children/adolescents (> 2 years) and < 60 ml/min/1.73 m2 in adults hScr, serum creatinine (mg/dL). Normal range: 0.6–1.2 (male), 0.5–1.1 (female) iHep2/Hep3, heparin-binding domain 2/3; IBD, integrin-binding domain; FN II/FN III, fibronectin type II/III domain; Ivs, intronic variant affecting splicing jTreatments:①Corticosteroids (e.g., prednisone); ②High-dose corticosteroids (e.g., methylprednisolone pulse therapy); ③RASi; ④Immunomodulators (e.g., mycophenolate mofetil); ⑤ Aspirin; ⑥ Other antihypertensives (e.g., calcium channel blockers); ⑦Traditional Chinese medicine; ⑧Sodium-glucose cotransporter-2 inhibitors(SGLT2i); ⑨ Rituximab; ⑩ Indomethacin kPR, partial remission; NR, no remission; KT, CKD stage 5 treated by kidney transplant; KF, kidney failure The clinical manifestations of FNG are non-specific, primarily characterized by proteinuria, which may be accompanied by hematuria, hypertension, and/or kidney impairment. Based on the literature review, proteinuria was the most common feature, occurring in 98.51% (66/67) of patients with available data. Hematuria was present in 53.73% (36/67) of cases, predominantly microscopic, although occasional reports of gross hematuria were noted [5, 7]. Hypertension was documented in 41.79% (28/67), and kidney insufficiency in 31.94% (23/72). The vast majority of the 72 patients exhibited proteinuria at initial presentation, while only a small number presented with hematuria, hypertension, or other symptoms as the chief complaint [7, 11]. Reports of childhood kidney failure in pediatric FNG cases are scarce in the available literature. A total of 26 distinct FN1 mutations have been reported worldwide in association with FNG based on literature review: c.1250G > T, c.2906C > T, c.2915A > G, c.2918A > G, c.2984C > T, c.3049 T > C, c.3051G > T, c.3415G > A, c.3910G > A, c.4374_4376del, c.4414_4416del, c.4415_4417del, c.5921 T > C, c.5602G > A, c.5688G > C, c.5749_5751delACT, c.5773 T > C, c.5775G > C, c.5821 T < C, c.5858_5884del, c.5888-1G > C, c.5888-2A > G, c.5921 T > C, c.5921 T > G, c.5962_5964del, c.6275C > T. Among these, 18 are located in the heparin-binding domain, 4 in the integrin-binding domain [9, 14, 26, 30], 2 are intron mutations [10, 12, 17], 1 occurs in the collagen-binding domain of FN II-2 [11], and 1 is situated in the central binding domain of FN III6 [18]. The c.2918A > G variant was the most prevalent, accounting for 27.78% (20/72) of cases. The heparin-binding domain represented the most frequent site of mutation (77.78%, 52/72), followed by the integrin-binding domain. Currently, no disease-specific therapy exists for FNG. Treatment remains supportive, primarily aimed at reducing proteinuria and controlling blood pressure to delay kidney function decline. Among the 72 patients analyzed, initial management strategies included glucocorticoids (21 cases), high-dose glucocorticoids (3 cases), renin–angiotensin system (RAS) inhibitors (22 cases), and immunosuppressants (9 cases). More recent reports have described the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) [12] and anti-CD20 monoclonal antibody therapy [34], with variable and often limited efficacy observed. For patients progressing to kidney failure, kidney replacement therapy via dialysis or transplantation is required. In this cohort, 22.22% (16/72) developed kidney failure. These cases involved variants located predominantly within the heparin-binding domain (c.2915A > G, c.2918A > G, c.3051G > T, c.5921 T > C, c.5773 T > C, c.5775G > C, c.5749_5751delACT), with one exception in the integrin-binding domain (c.4414_4416del). Notably, disease recurrence after kidney transplantation was reported in 25.00% (4/16) of cases, associated with variants c.2918A > G [15], c.5921 T > C [21], and c.5773 T > A [4]. Discussion FNG is a chronic kidney disease primarily caused by FN1 gene variants, characterized clinically by proteinuria and potential progression to kidney failure. This study reports a case of childhood-onset FNG resulting from a heterozygous FN1 variant (c.5749_5751delACT, p.Thr1917del). The patient presented with massive proteinuria and microscopic hematuria during school age. The clinical course was marked by partial response to corticosteroids but gradual deterioration of kidney function, culminating in kidney failure 10 years after the initial clinical presentation. The FN1 gene (OMIM #135,600) is located on chromosome 2q35 and encodes FN, a high-molecular-weight glycoprotein that exists in two principal forms: cellular fibronectin (cFN), an insoluble component of the cell surface and extracellular matrix (ECM), and plasma fibronectin (pFN), a soluble dimeric protein secreted mainly by hepatocytes into the bloodstream [35, 36]. The FN dimer is stabilized by disulfide bonds at the C-terminus, with each monomer consisting of 12 type I domains (FNI1-12), two type II domains (FNII1-2), and 15 type III domains (FNIII1-15), along with variable segments (EDA, EDB, IIICS). These modular domains play critical roles in protein assembly and interactions with other ECM components [37]. Functional domains include three heparin-binding domains: Hep-I (located in FI1-4), Hep-II (FIII12-14), and Hep-III (FIII4-5) and one integrin-binding domain (IBD within FIII9-10) (Fig. 4). Evolutionarily conserved protein domains are essential for understanding phylogenetic relationships, molecular functions, and their potential as therapeutic targets [38]. Among them, the heparin-binding domain Hep-III has been recognized as a key regulator of FN matrix assembly. In the present case, the identified p.Thr1917del mutation is situated in exon 36 of the FN1 gene, within the heparin-binding domain 2 (Hep-II), a region critical for proper FN folding, dimerization, and ECM binding. The in-frame deletion of three nucleotides results in the loss of a conserved threonine residue, likely disrupting local hydrogen bonding or spatial conformation, thereby impairing dimer assembly and secretion. This molecular defect leads to production of FN with compromised heparin-binding capacity, reducing its ability to incorporate properly into the ECM. Consequently, excessive FN accumulates and deposits within the glomeruli, ultimately driving progressive kidney injury [2, 4, 24]. This mechanism offers a plausible explanation for the early-onset and aggressive clinical phenotype observed in this pediatric patient. While FNG can present at any age, its onset predominantly occurs between 20 and 50 years (51.39%). Most patients exhibit normal kidney function at diagnosis, with progression to kidney failure typically occurring 15–20 years after clinical manifestation [33]. In contrast, the current case presented at 7 years of age, classifying it as early-onset pediatric FNG (≤ 18 years, accounting for 30.55% of cases), which aligns with previous reports of young children by Yang et al. [7] and Kalmár et al. [11]. Notably, this patient progressed to kidney failure within only 10 years, indicating a relatively rapid disease course. This rapid course stands in contrast to the more indolent progression typically described in both adult and pediatric FNG literature. The rate of kidney functional decline in FNG shows considerable heterogeneity, as evidenced by variability in outcomes even among family members carrying the same mutation, such as the most common p.Tyr973Cys variant [23, 32]. In some families, one affected individual may progress to kidney failure while another shows no signs of urinary or kidney abnormalities [39, 40]. This heterogeneity suggests that, in addition to genotype, other factors—such as comorbidities like diabetes and obesity, hypertension, degree of proteinuria, and nonspecific inflammation—may collectively influence the natural history of the disease [41]. A 2019 retrospective analysis by Zhang et al. of 19 FNG patients from a single center identified nephrotic-range proteinuria and focal glomerulosclerosis as factors associated with kidney functional decline, whereas tubulointerstitial fibrosis or vascular changes showed no clear correlation with kidney outcome [42]. In the present case, the patient had persistent heavy proteinuria throughout the clinical course, and kidney pathology at year 6 showed global focal segmental glomerulosclerosis. These features likely acted as major drivers accelerating the decline in kidney function. Both the present case and the literature review indicate that FNG exhibits variable and often suboptimal responses to therapies including corticosteroids, immunosuppressants (such as MMF or tacrolimus), and RAS inhibitors. Most patients show only partial or transient benefit, if any. In the current case, proteinuria decreased temporarily with early corticosteroid treatment, yet kidney function continued to decline progressively. This observation aligns with the underlying pathophysiology of FNG, which is driven by abnormal structural protein deposition rather than typical immune-mediated inflammation, suggesting that decisions regarding immunosuppressive therapy should be highly individualized. Current management emphasizes foundational supportive care, consistent with chronic kidney disease guidelines, including the use of RAS inhibitors and SGLT2i, along with strict control of blood pressure, blood glucose, and lipid levels. Lifestyle modifications such as a balanced diet and regular physical activity are also recommended [41]. Ultimately, the development of targeted therapies, including potential gene-based interventions, will be essential to effectively alter the disease course. Both the present case and aggregated literature data indicate that approximately 22.2% (16/72) of FNG patients progress to kidney failure, with mutations in heparin-binding domains—particularly Hep2 and Hep3—appearing to confer a higher risk of kidney failure. Notably, disease recurrence after kidney transplantation has been repeatedly documented, with a recurrence rate of 25% (4/16) in our pooled analysis. Histologically confirmed recurrence occurred between 7 months and 12 years post-transplant, whereas proteinuria emerged significantly earlier [15]. The variable recurrence rate post-transplant may be influenced by the specific FN1 mutation, the duration of post-transplant follow-up (which was inconsistently reported in the literature), and potentially other modifying genetic or environmental factors. Longer-term follow-up studies are needed. The mechanism underlying post-transplant recurrence is attributed to renewed deposition of mutant plasma fibronectin (pFN) circulating in the recipient and accumulating in the kidney allograft. This concept is supported by the work of Moretti et al., which demonstrated that pFN constitutes a major source of tissue fibronectin, accounting for up to 60% of fibronectin present in the extracellular matrix of certain tissues [43]. Consequently, long-term meticulous follow-up is essential for patients with FNG who undergo kidney transplantation. The characteristic light microscopic findings in FNG include glomerular enlargement with accentuated lobular architecture, accompanied by substantial electron-dense deposits in the mesangial and subendothelial regions. Ultrastructural examination reveals that these deposits are predominantly amorphous or granular and are typically confined to the mesangium and outer capillary loops [44]. Consequently, definitive diagnosis requires positive fibronectin immunohistochemical staining of kidney tissue. It is noteworthy that numerous reported cases, including the present one, were initially misdiagnosed as MPGN. Other documented diagnostic misinterpretations include IgA nephropathy [16], lupus nephritis [21], Alport syndrome [7], and thin basement membrane nephropathy [18]. The light microscopic features of FNG show close resemblance to those of immune-complex-mediated glomerulonephritis, underscoring the importance of careful differential diagnosis. We recommend performing fibronectin immunohistochemistry when kidney biopsy reveals the following characteristics: glomerular enlargement with lobular configuration observed by light microscopy, abundant PAS-positive and fuchsinophilic deposits in mesangial and subendothelial regions, immunofluorescence demonstrating negligible or only weak immunoglobulin deposition, and numerous granular electron-dense deposits located in mesangial and peripheral capillary wall areas. Although FNG has historically been regarded as a kidney-limited disorder, the pathological basis for systemic deposition in patients presenting with extra-kidney manifestations has remained poorly understood. Previous investigations failed to detect FN deposits in organs including lungs, heart, brain, liver, and spleen [39]. However, studies have documented increased FN expression in esophageal adenocarcinoma compared to normal gastric mucosa [45]. Lin et al. proposed that FN may facilitate malignant tumor growth and metastasis [46]. Furthermore, clustered occurrences of cerebral hemorrhage within FNG families [23, 39] and research by Scholze et al. suggesting plasma fibronectin's potential role in thrombogenesis and cardiovascular complications [47], have indicated possible systemic pathology. The 2021 report by Hara et al. [24] provided the first description of FN deposits in extra-kidney vascular walls of patients with FNG. To directly examine whether FN1 mutations lead to systemic FN deposition, we conducted FN immunohistochemistry on the patient's gastric mucosal biopsy specimen compared with normal controls. Our analysis demonstrated substantially enhanced FN staining within ECM of the lamina propria, consistent with abnormal ECM deposition. This observation indicates that FNG may represent a systemic protein deposition disorder and emphasizes the importance of assessing potential multiorgan involvement in clinical management. This investigation is constrained by its single-case design and the lack of functional validation regarding the pathogenicity of the p.Thr1917del variant. However, this case-centered review was not designed to perform a formal comparative analysis between variants in the heparin-binding domain and those in other regions. Future research should employ patient-derived induced pluripotent stem cell (iPSC)-differentiated kidney organoids or establish animal models to directly verify its pathogenic effect and clarify the specific molecular mechanisms responsible for disrupted FN assembly. Conclusion This study describes the first pediatric case of rapidly progressive FNG resulting from a novel FN1 p.Thr1917del mutation, thereby expanding both the mutational spectrum and phenotypic range of this disease. For patients presenting with persistent proteinuria, with or without hematuria or hypertension, whose kidney biopsy demonstrates enlarged glomeruli with lobular accentuation and abundant electron-dense deposits in mesangial and subendothelial regions, fibronectin immunohistochemistry and FN1 gene sequencing should be implemented to achieve accurate diagnosis. While current treatment strategies remain primarily supportive, enhanced understanding of disease pathogenesis may facilitate the development of targeted therapies directed at abnormal FN synthesis, secretion, or clearance, potentially improving long-term patient outcomes. The identified ECM deposition of fibronectin in gastric mucosa provides compelling evidence redefining FNG as a systemic disorder, thereby establishing a theoretical framework for future targeted therapies aimed at circulating pathogenic protein. Supplementary information Below is the link to the electronic supplementary material. ESM 1Graphical abstract (PPTX 1.49 MB) Graphical abstract (PPTX 1.49 MB)